FDA clears first GLP‑1 pill

These drugs work by copying a gut hormone called glucagon-like peptide 1, which is one of the body’s “I’m full now” signals after a meal. That signal slows stomach emptying and reduces appetite, which is why the same drug class now shows up in both diabetes care and obesity treatment. (fda.gov) The hard part has been turning that hormone effect into a pill people can actually live with. Earlier oral versions needed careful timing because food and water could change how much drug the body absorbed. (novo-pi.com) The new approval changes that routine. On April 1, 2026, the Food and Drug Administration cleared Foundayo, the brand name for orforglipron, as a once-daily tablet for adults with obesity or adults who are overweight and have at least one weight-related medical condition. (fda.gov) Foundayo is not semaglutide. It is orforglipron, a different glucagon-like peptide 1 drug made by Eli Lilly, and the Food and Drug Administration says it can be taken once daily with or without food. (fda.gov) (pi.lilly.com) That “with or without food” detail is the whole story in one line. A weight-loss medicine that acts like this hormone but fits into a normal breakfast, lunch, or bedtime routine is a very different product from a medicine that has to be scheduled around an empty stomach. (pi.lilly.com) (novo-pi.com) The dose is also built like a staircase instead of a light switch. The label starts patients at 0.8 milligrams once daily, then steps up after at least 30 days to 2.5 milligrams, then 5.5 milligrams, with optional increases to 9, 14.5, and 17.2 milligrams based on response and side effects. (pi.lilly.com) The side effects will sound familiar to anyone who has followed this drug class. The label warns about nausea, vomiting, diarrhea, constipation, pancreatitis, kidney injury from dehydration, and a boxed warning tied to thyroid C-cell tumor findings seen with glucagon-like peptide 1 drugs in rodents. (dailymed.nlm.nih.gov) In the phase 3 ATTAIN-1 obesity trial, adults without diabetes taking the highest dose lost an average of 12.4% of body weight, or 27.3 pounds, at 72 weeks among treatment-adherent participants. The placebo-adjusted weight reduction was roughly 9 to 11 percentage points across doses. (ajmc.com) (acc.org) This approval also landed unusually fast. The Food and Drug Administration said Foundayo was cleared 50 days after filing, which made it the first new molecular entity approved under the agency’s Commissioner’s National Priority Voucher pilot program and the fastest approval of a new molecular entity since 2002. (fda.gov) Patients now have a simpler choice to compare against the weekly shot: trade some of the injection burden for a daily pill, then weigh convenience, weight loss, side effects, insurance coverage, and how reliably they can stay on treatment for 72 weeks or longer. The science is still the same appetite signal, but the daily routine around it just got much easier. (fda.gov) (pi.lilly.com)